Moderna, Inc. (MRNA)
MRNA moved a median of -0.09% 30 minutes after news, and -0.19% by the close. How MRNA actually reacts to news — the realized, point-in-time move the market made, measured across 1,089 labeled events over the last three years with zero look-ahead.
MRNA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.12% | 41% | 1,086 |
| 30-min | -0.09% | 47% | 1,086 |
| 60-min | -0.07% | 48% | 1,086 |
| to close | -0.19% | 47% | 1,086 |
| Middle 50% of MRNA reactions | -1.06% to +0.68% |
|---|---|
| Median reaction (30-min) | -0.09% |
| Measured reactions | 1,089 |
Half of all Moderna, Inc. news events land between -1.06% and +0.68% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MRNA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 31 | +0.55% | 68% | +3.00% |
| Analyst downgrades | 32 | +1.06% | 66% | +3.19% |
| Coverage initiations | 27 | +1.70% | 59% | -0.40% |
| Rating reiterations | 146 | -0.27% | 46% | -0.15% |
| Price-target raises | 16 | +0.24% | 56% | +0.66% |
| Price-target cuts | 41 | -0.34% | 37% | +0.29% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how MRNA ranks against every other measured name →
That’s how MRNA usually reacts — get an email when it moves on news →Email me when MRNA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MRNA's baseline. Nothing else.
Recent MRNA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 | Press release | ACCESS Newswire | +1.19% | +4.15% | |
| Form 8-K Moderna, Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +1.76% | +3.54% | |
| Moderna Adds Chief Operating Officer Role as Company Expands into Oncology | Press release | ACCESS Newswire | +1.76% | +3.54% | |
| Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026 | Press release | ACCESS Newswire | -0.06% | +3.36% | |
| Form 8-K Moderna, Inc. For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | +1.17% | -1.10% | |
| Moderna to Present at Upcoming Conferences in September 2026 | Press release | ACCESS Newswire | -0.99% | +10.23% | |
| Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes | Press release | ACCESS Newswire | -1.09% | +0.54% | |
| Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes | Press release | ACCESS Newswire | -1.41% | -1.54% | |
| Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines | Press release | ACCESS Newswire | -0.61% | -0.61% | |
| Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA | Press release | ACCESS Newswire | -0.78% | -6.44% | |
| Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus | Press release | ACCESS Newswire | +0.19% | +0.07% | |
| Form 10-Q Moderna, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.42% | +0.71% | |
| Form 8-K Moderna, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +0.88% | -4.01% | |
| Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | ACCESS Newswire | +0.88% | -4.01% | |
| Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors | Press release | ACCESS Newswire | +0.42% | -5.63% | |
| Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026 | Press release | ACCESS Newswire | +1.63% | +3.74% | |
| Form 8-K Moderna, Inc. For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | -2.67% | -5.38% | |
| Moderna Appoints Michael McDonnell to Board of Directors | Press release | ACCESS Newswire | -2.67% | -5.38% | |
| Moderna Science Day Highlights Expanding Potential of mRNA Platform | Press release | ACCESS Newswire | +0.45% | -0.96% | |
| Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine | Press release | ACCESS Newswire | -4.92% | -7.27% | |
| Moderna to Host Investor Event - Science Day | Press release | ACCESS Newswire | -0.71% | +10.36% | |
| Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028 | Press release | ACCESS Newswire | +1.40% | +6.46% | |
| Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome | Press release | ACCESS Newswire | -1.28% | -1.43% | |
| Moderna to Present at Upcoming Conference in June 2026 | Press release | ACCESS Newswire | -2.17% | +0.84% | |
| Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus | Press release | ACCESS Newswire | -1.34% | -1.85% | |
| Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting | Press release | ACCESS Newswire | -1.34% | -1.85% | |
| Moderna Recognized by TIME as One of the World's Most Impactful Companies | Press release | ACCESS Newswire | -3.26% | -4.62% | |
| Form 8-K Moderna, Inc. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -1.05% | -8.95% | |
| Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 | Press release | ACCESS Newswire | +0.15% | -5.78% | |
| Form 10-Q Moderna, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.75% | +3.96% | |
| Form 8-K Moderna, Inc. For: May 01 | SEC filing · Form 8-K | SEC EDGAR | -2.86% | -2.70% | |
| Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | ACCESS Newswire | -2.86% | -2.70% | |
| Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting | Press release | ACCESS Newswire | +1.43% | +2.16% | |
| Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Press release | ACCESS Newswire | -0.63% | +0.09% | |
| Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 | Press release | ACCESS Newswire | -0.17% | +1.78% | |
| Moderna to Present at Upcoming Conferences in May 2026 | Press release | ACCESS Newswire | -2.62% | +0.61% | |
| Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting | Press release | ACCESS Newswire | +1.34% | -1.91% | |
| Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026 | Press release | ACCESS Newswire | +1.06% | +0.57% | |
| Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | Press release | ACCESS Newswire | -1.75% | +2.90% | |
| Form ARS Moderna, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.86% | +0.80% | |
| Form DEF 14A Moderna, Inc. For: May 06 | SEC filing · Form DEF | SEC EDGAR | +0.86% | +0.80% | |
| Form DEFA14A Moderna, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.86% | +0.80% | |
| Form 8-K Moderna, Inc. For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | +1.69% | -5.50% | |
| Moderna Resolves Global Patent Litigation with Arbutus/Genevant | Press release | ACCESS Newswire | -2.99% | +7.88% | |
| European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 | Press release | ACCESS Newswire | +1.12% | +4.16% | |
| Form 10-K Moderna, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.72% | +2.97% | |
| Form S-8 Moderna, Inc. | SEC filing · Form S-8 | SEC EDGAR | +4.72% | +2.97% | |
| Moderna to Present at Upcoming Conferences in March 2026 | Press release | ACCESS Newswire | -1.83% | +5.90% | |
| Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission | Press release | ACCESS Newswire | -0.76% | -0.19% | |
| Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE | Press release | ACCESS Newswire | +3.53% | +4.08% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MRNA section they belong to.
Where else MRNA is measured.
MRNA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Moderna, Inc.'s median reaction calculated?
Every labeled MRNA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,089 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of MRNA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MRNA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.